Journal of Eating Disorders
February 17, 2026
Stéphanie Knatz Peck, Timothy D Brewerton
In our original case report we provide detailed accounts of two research participants who reported the emergence of spontaneously recovered, previously forgotten traumatic memories of sexual assaults during psilocybin treatment. In their commentary of this article, Kangaslampi et al. argue that we preemptively label the experiences as dissociated traumatic memories in the absence of...
BJPsych Open
February 16, 2026
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
1 citation
BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
Journal of Psychopharmacology
February 16, 2026
Marten Kase, Karl Kristjan Kaup, Jaan Aru
1 citation
We carried out a systematic review of modern-era (1990-2025) placebo-controlled studies assessing the acute and post-acute effects of lysergic acid diethylamide, dimethyltryptamine and psilocybin on cognitive and psychological functions. From February 28 to March 19, 2025, PubMed and APA PsychINFO were systematically searched for placebo-controlled studies examining the influence of...
Translational Psychiatry
February 14, 2026
Michael H Sutherland, Christopher R. Nicholas, Richard C Lennertz et al.
The serotonergic psychedelic psilocybin induces neural plasticity and profoundly alters consciousness. The benzodiazepine midazolam blunts neural plasticity and induces conscious sedation and amnesia at low doses. In our recent open label pilot study, we administered oral psilocybin (25 mg) along with intravenous midazolam at doses allowing a full psychedelic experience while blunting memory...
Scientific Reports
February 14, 2026
Zurika Murray, Angélique Lewies, Johannes F. Wentzel et al.
3 citations
The therapeutic potential of psilocybin in treating psychiatric disorders has gained attention recently. While most research has focused on isolated psilocybin, evidence suggests that whole mushroom extracts exhibit greater efficacy, implicating a possible entourage effect of additional bioactive compounds. This study aimed to elucidate the holistic neuropharmacological effects of...
Neuropsychopharmacology
February 13, 2026
Fabrizio Ascone, Valeria Buzzelli, Francesca Mottarlini et al.
2 citations
Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a synaptic disorder, FXS involves the loss of Fragile X messenger ribonucleoprotein 1 (FMRP), leading to abnormal dendrite development and immature dendritic spines. Serotonergic signaling, essential for neuronal development and circuit remodeling,...
Journal of Affective Disorders
February 12, 2026
Erica Kaczmarek, Nelson Rodriguez, Noah Chisamore et al.
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary analysis aimed to evaluate the effects of psilocybin-assisted psychotherapy (PAP) on anhedonia severity in individuals with treatment-resistant depression (TRD). Participants (n = 30) with TRD and a primary diagnosis of Major Depressive Disorder or...
Molecular Psychiatry
February 12, 2026
Sixtine Fleury, Katherine M. Nautiyal
correction
should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral and neural effects of psilocybin in mice."The final sentence of the Introduction should have read "Our findings suggest that the 5-HT1BR influences brain-wide neural changes following psilocybin administration and may contribute to its enduring...
Journal of Psychedelic Studies
February 12, 2026
Matthew Hicks, Olivia Hicks, Ryan Bradley et al.
2 citations
Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. This study was designed to test the feasibility of conducting group psilocybin therapy in low-income adults with depression in Oregon's regulated psilocybin program. Methods An open label, uncontrolled design was used. After a medical screening...
February 11, 2026
Sarah Shnayder, Gabrielle Agin-Liebes, Troy Hubert et al.
preprint
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsessive-compulsive disorder (OCD)....